Comparison of Two PPOS Models for Pituitary Suppression

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-34
SponsorNextFertility

About this trial

The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.

Eligibility criteria

Qualifiers

BMI of 18-29,9 kg/m2

Ultrasound count of antral follicles prior to COH ≥ 12 follicles

Meeting the criteria for inclusion in the egg donation program

Normal karyotype and no active sexually transmitted diseases

Disqualifiers

Patients excluded from the egg donation program

Untreated sexually transmitted diseases, positive serology for HBV, HIV, HCV

Blood disorders, neurodegenerative/psychiatric diseases, carriers of X-linked genetic diseases, oncological diseases, endometriosis.

Oligomenorrhea (<1 menstrual cycle in 3 months)

Trial design

Treatments tested in this trial

  • Cerazet

Treatment groups

210 Participants
are divided into 2 treatment groups

Sponsors and collaborators

NextFertility

Lead sponsor

SINAE SL

Collaborator